Advisor Dumps $5.1 Million Stake in FMC Amid a 69% Stock Collapse

Oregon-based tru Independence fully liquidated its 152,855-share position in FMC (estimated $5.14M) as of Jan. 22, removing the stock from its 132 reportable holdings after FMC previously represented ~1.3% of the fund’s AUM. FMC is trading at $16.02 (down ~69% Y/Y) with trailing revenue of $3.61B and a TTM net loss of $531.8M; Q3 revenue plunged 49% YoY while adjusted EBITDA rose 17% to $236M amid an India divestiture and cost cuts. Management has prioritized balance-sheet repair — cutting the dividend to $0.08 and guiding to roughly breakeven full-year free cash flow — making this exit a reallocation away from a company undergoing major restructuring rather than a steady growth compounder.

Analysis

Market structure: tru Independence’s exit of FMC (NYSE:FMC) is a reallocative flow, not a sector shock — direct beneficiaries are competitors with cleaner balance sheets (e.g., Corteva CTVA) and passive/factor ETFs that capture larger-cap, diversified ag-players. FMC holders and short-duration creditors are hurt as the 69% 1‑yr share collapse and dividend cut signal constrained free cash flow and potential credit stress; expect increased bid/ask dispersion and lower retail demand for FMC shares near $16.

Risk assessment: Near term (days–weeks) volatility will stay elevated around earnings and the India divestiture timeline; short-term (1–6 months) risks include a credit-rating downgrade and litigation/regulatory shocks to crop-chemical approvals; long-term (6–24 months) recovery hinges on successful India sale, sustained positive free cash flow (>+$100m annual) and market-share retention. Hidden dependencies include FX exposure in emerging markets (INR/BRL) affecting reported revenue and working‑capital swings; a failed divestiture or adverse regulatory ruling is a low‑probability, high‑impact tail that could wipe equity value.

Trade implications: Tactical short-biased plays on FMC (defined-risk put spreads) and a relative long in CTVA (market-share and balance-sheet advantage) are attractive over 3–12 months. Cross-asset: expect modest widening in FMC credit spreads (corporate bonds) — consider short protection on higher‑beta agribusiness bond ETFs; commodity/FX flows are second order but adverse weather could flip demand for crop protection and help FMC.

Contrarian angles: The sell-off may over-penalize FMC’s remaining franchise in specialty chem/biologicals; if India sale closes and management demonstrates FCF positive quarters (two consecutive), upside re-rating is plausible. Consider small, asymmetric option exposure (12‑month calls) only after verifiable operational inflection; absent that, price action suggests value-trap risk rather than deep-value opportunity.

Key Decisions for Investors

• Establish a tactical, defined‑risk short on FMC: buy 3‑month put spread (buy $15 / sell $10) sizing to 0.5% of portfolio notional; take profit if FMC < $10 or after 30% premium decay reduction, stop-loss if FMC > $22.
• Implement a 12‑month pair trade: go long Corteva (CTVA) equal to 2.0% of portfolio and short FMC equal to 1.0% of portfolio (net exposure biased long CTVA). Target +30% on the long or cut at -12%; cover the short if FMC shows two consecutive quarters of FCF > $25m.
• Reduce aggregate exposure to pure-play crop‑chemical equities by 3% and redeploy into precision/biological agriculture exposure: buy VanEck Agribusiness ETF (MOO) 2% allocation and Deere (DE) 1% allocation, holding 6–12 months to capture defensive demand and machinery/tech tailwinds.
• Monitor specific catalysts over next 90 days: (1) closing of India divestiture, (2) quarterly FCF print and net debt/EBITDA trend. If two of three positive (India sale closed, FCF positive quarter, net debt/EBITDA <3x), initiate a 12‑month FMC call position sized 0.25% (e.g., long $25 calls) for asymmetric upside.